19-23649-shl Doc 621 Filed 12/06/19 Entered 12/06/19 19:17:35 Main Document 19-23649-rdd Doc 548 Filed 11/26/19 Entered 11/26/19 16:31:39 Main Document Pg 13 of 20

UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK	_				
In re:	Chapter 11				
PURDUE PHARMA L.P., et al.,	Case No. 19-23649 (RDD)				
Debtors. ¹	(Jointly Administered)				
AFFIDAVIT AND DISCLOSURI	ABE,IKUBOR ESTATEMENT OF <u>KATAYAMA</u> ,				
ON BEHALF OF Pu	irdue Pharma L.P.				
STATE OF)					
COUNTY OF) s.s.:					
Tomohisa <u>Sugirama</u> , being duly sworn,	upon his oath, deposes and says as follows:				
1. I am a patent attui	rney of ABE, IKUBO & KATAYAMA				
Fukuoka Building, 8-7, located at <u>Chyo-ku, Tokyo, JAPA</u>	rney of ABE, IKUBO & KATAYAMA, Yaesu 2 Chome, (the "Firm").				
2. Purdue Pharma L.P. and	its affiliates that are debtors and debtors in				
possession in the above-captioned chapter 11 cas	es (collectively, the "Debtors"), have requested				
that the Firm provide services to the Debtors,	and the Firm has consented to provide such				
services (the "Services").					
3. The Services include, but a	re not limited to, the following:				
patent filing and prosecution in	Japan, opinion work				

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

19-23649-shl Doc 621 Filed 12/06/19 Entered 12/06/19 19:17:35 Main Document 19-23649-rdd Doc 548 Filed 11/26/19 Entered 11/26/19 16:31:39 Main Document Pg 14 of 20

- 4. The Firm may have performed services in the past and may perform services in the future, in matters unrelated to these chapter 11 cases, for persons that are parties in interest in the Debtors' chapter 11 cases. As part of its customary practice, the Firm is retained in cases, proceedings, and transactions involving many different parties, some of whom may represent or be claimants or employees of the Debtors, or other parties in interest in these chapter 11 cases. The Firm does not perform services for any such person in connection with these chapter 11 cases. In addition, the Firm does not have any relationship with any such person, such person's attorneys, or such person's accountants that would be adverse to the Debtors or their estates with respect to the matters on which the Firm is to be retained.
- 5. Neither I, nor any principal of, or professional employed by the Firm has agreed to share or will share any portion of the compensation to be received from the Debtors with any other person other than principals and regular employees of the Firm.
- 6. Neither I nor any principal of, or professional employed by the Firm, insofar as I have been able to ascertain, holds or represents any interest materially adverse to the Debtors or their estates with respect to the matters on which the Firm is to be retained.

19-23649-shl Doc 621 Filed 12/06/19 Entered 12/06/19 19:17:35 Main Document Pg 3 of 8 19-23649-rdd Doc 548 Filed 11/26/19 Entered 11/26/19 16:31:39 Main Document Pg 15 of 20

- 7. As of the commencement of this chapter 11 case, the Debtors owed the Firm \$ 6,500 in respect of prepetition services rendered to the Debtors.
- 8. The Firm is conducting further inquiries regarding its retention by any creditors of the Debtors, and upon conclusion of this inquiry, or at any time during the period of its employment, if the Firm should discover any facts bearing on the matters described herein, the Firm will supplement the information contained in this Affidavit.

Pursuant to 28 U.S.C. § 1746, I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct, and that this Affidavit and Disclosure Statement was executed on <u>December 6</u>, 2019, at <u>Tokyo JAPAN</u>.

Tomohisa Sugiyama
Affiant Name

SWORN TO AND SUBSCRIBED before Me this finday of Lecenser, 2019

Notary Public Motobiro VOSHIDA

TOKYO LEGAL AFFAIRS BUREAU

NOTARY

1-10.1 CHOME KYOBASHI CHUO-KU
TOKYO JAPAN

19-23649-shl Doc 621 Filed 12/06/19 Entered 12/06/19 19:17:35 Main Document 19-23649-rdd Doc 548 Filed 11/26/19 Entered 11/26/19 16:31:39 Main Document Pg 17 of 20

UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK

In re:

PURDUE PHARMA L.P., et al.,

Debtors.4

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

RETENTION QUESTIONNAIRE

TO BE COMPLETED BY PROFESSIONALS EMPLOYED by Purdue Pharma L.P. and its affiliates that are debtors and debtors in possession in the above-captioned cases (collectively, the "**Debtors**").

All questions **must** be answered. Please use "none," "not applicable," or "N/A," as appropriate. If more space is needed, please complete on a separate page and attach.

1. Name and address of professional:

Tomohisa Sugiyama

Fukuoka Building, 8-7, Yaesu 2 Chome, Chuo-ku, Tokyo, JAPAN

2. Date of retention: April 25, 2002

3. Type of services to be provided:

Patent filing and prosecution in Japan, opinion work

⁴ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

#92634797v5

19-23649-s 19-23649-	hl Doc 62 rdd Doc 5	1 Filed 48 Filed	11/26/1 ^{Pg}	Entered 5 of 8 Entered 18 of 20	11/26/19	L9 19:17:35 0 16:31:39	Main Document Main Document	
						0 0 6	r	
4.	Brief descri	ption of se	rvices to be p	rovided:				
	IP ser	vices	relating	to pat	ent	filing an	d prosecution	
5.	Arrangemen	its for com	pensation (ho	ourly, cont	ingent, et	c.):		
		rerage	hourly	re	ite	(if	applicable):	
	\$ 341	0/h						
			erage monthl		sation ba	sed on prepet	ition retention	
	N/	'A						
6.	Prepetition claims against the Debtors held by the company:							
	Amount of c	claim: \$	6,500					
	Date claim a	rose: be	tween J				ptember 30,201	

Nature of claim: Patent prosecution

19-23649-shl Doc 621 Filed 12/06/19 Entered 12/06/19 19:17:35 Main Document 19-23649-rdd Doc 548 Filed 11/26/19 Entered 11/26/19 16:31:39 Main Document Pg 19 of 20

	repetition claims against the Debtors held individually by any membersociate, or employee of the company:
N	ame: N/A
S	ratus: N/A
	mount of claim: \$ N/A
	ate claim arose: N/A
N	ature of claim: N/A
_	
_	
L	isclose the nature and provide a brief description of any interest adverse to the ebtors or to their estates for the matters on which the professional is to apployed:
Γ	ebtors or to their estates for the matters on which the professional is to
Γ	ebtors or to their estates for the matters on which the professional is to apployed: N/A
Γ	ebtors or to their estates for the matters on which the professional is to apployed:
Γ	ebtors or to their estates for the matters on which the professional is to apployed: N/A
E en an or control de	ebtors or to their estates for the matters on which the professional is to apployed: N/A

19-23649-s 19-23649	shl -rdd	Doc 621 Doc 548	Filed 12/06/3	19 19 ⁹ Pg	Entered 7 of 8 Entered 20 of 20	12/06/19 11/26/19	9 19:17:35 16:31:39	Main Docur Maiກັ້ Documer	nent it
	_								
10.			f individual con	•	J	_	ner		

Dated: December 6, 2019

認

証

嘱託人・阿部・井窪・片山法律事務所の弁理士 杉山 共永 (Mr. Tomohisa Sugiyama) は、本公証人の面前において、添付書面に署名した。

よって、これを認証する。

令和元年 12月 6日、本公証人役場において

東京都中央区京橋一丁目1番10号

東京法務局所属 公証人 Notary Motohiro YOSHIDA


証明

上記署名は、東京法務局所属公証人の署名に相違ないものであり、かつ、その押印は、 真実のものであることを証明する。

令和元年 12月 6日

東京法務局長

山西宏系



APOSTILLE

(Convention de La Haye du 5 octobre 1961)

- 1. Country: JAPAN

 This public document
 - This public document
- 2. has been signed by Motohiro YOSHIDA
- 3. acting in the capacity of Notary of the Tokyo Legal Affairs Bureau
- 4. bears the seal/stamp of Motohiro YOSHIDA, Notary

 Certified
- 5. at Tokyo

- 6. DEC. 6. 2019
- 7. by the Ministry of Foreign Affairs
- 8. 19- Nº 131193
- 9. Seal/stamp:

10. Signature



T. TANAKA

Toshie TANAKA

For the Minister for Foreign Affairs